Key result
Intravenous magnesium premedication significantly reduced grade 2 or higher nephrotoxicity compared to no premedication (2.5% vs 21.5%, p=0.0026) in patients receiving neoadjuvant chemotherapy.
Why the study?
The effectiveness of magnesium premedication in reducing cisplatin-induced nephrotoxicity was unknown in esophageal cancer, particularly regarding neoadjuvant therapy.
Does intravenous magnesium premedication reduce cisplatin-induced nephrotoxicity in patients with esophageal cancer undergoing neoadjuvant chemotherapy?
Cohort (n=105)
Does intravenous magnesium premedication reduce cisplatin-induced nephrotoxicity in patients with esophageal cancer undergoing neoadjuvant chemotherapy?
Absolute Event Rate: 2.5% vs 21.5%
p-value: p=0.0026
Intravenous magnesium premedication significantly reduces the incidence of grade 2 or higher cisplatin-induced nephrotoxicity in patients with esophageal cancer undergoing neoadjuvant chemotherapy.
May support magnesium premedication to lower cisplatin nephrotoxicity risk; leaves open randomized confirmation in esophageal cancer.
BACKGROUND: Magnesium premedication is reported to have a significant effect on reducing cisplatin-induced nephrotoxicity in several types of cancer. However, the effectiveness of magnesium administration in reducing nephrotoxicity remains unknown in esophageal cancer, especially regarding neoadjuvant therapy. METHODS: Between January 2017 and January 2019, 105 patients who underwent neoadjuvant chemotherapy followed by surgery were included in this study. Of these patients, 40 received intravenous magnesium premedication (magnesium group), whereas the remaining 65 did not (control group). We investigated the -association between magnesium premedication and chemotherapy-related nephrotoxicity. RESULTS: Baseline characteristics, such as age, body mass index, clinical stage, comorbidity, and pretreatment renal function, were not significantly different -between the magnesium and control groups. Clinical and -pathological responses were similar between the 2 groups. Regarding chemotherapy-related toxicity, there were no significant differences in hematological side effects, such as anemia, thrombopenia, and neutropenia, between both groups. However, nephrotoxicity of grade 2 and higher was significantly less frequent in the magnesium group than in the control group (2.5 vs. 21.5%, p = 0.0026), although there was no significant difference in the incidence of other nonhematological adverse events, such as nausea and diarrhea. Multivariate analysis indicated magnesium premedication and heart disease as independent factors associated with cisplatin-induced nephrotoxicity (p = 0.0026 and p = 0.0424, respectively). CONCLUSION: We showed that intravenous magnesium premedication exerts a protective effect against renal dysfunction in esophageal cancer patients undergoing neoadjuvant chemotherapy including high-dose cisplatin. Large-scale prospective studies are needed to confirm the effect of magnesium premedication on reducing nephrotoxicity in esophageal cancer patients undergoing neoadjuvant therapy.
No takes yet. Share an insight, caveat, or question.
Kubo et al. (2019) conducted a cohort in Esophageal cancer (n=105). Intravenous magnesium premedication vs. No magnesium premedication was evaluated on Nephrotoxicity of grade 2 and higher (p=0.0026). Intravenous magnesium premedication significantly reduced grade 2 or higher nephrotoxicity compared to no premedication (2.5% vs 21.5%, p=0.0026) in patients receiving neoadjuvant chemotherapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: